E. Parmee

发表

Potent and selective proline derived dipeptidyl peptidase IV inhibitors.

N. Thornberry, B. Leiting, Sanjeev Kumar, 2004, Bioorganic & medicinal chemistry letters.

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.

Ping Chen, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

Aleksandr Petrov, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

Discovery and Development Of The DPP‐4 Inhibitor Januvia™ (Sita‐Gliptin)

Feng Xu, R. Sinharoy, E. Parmee, 2012 .

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

A novel series of indazole-/indole-based glucagon receptor antagonists.

S. Qureshi, Bei B. Zhang, G. Salituro, 2015, Bioorganic & medicinal chemistry letters.

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

V. Ding, Bei B. Zhang, J. Tata, 2007, Bioorganic & medicinal chemistry letters.

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

V. Ding, S. Qureshi, K. Chapman, 2005, Bioorganic & medicinal chemistry letters.

The importance of synthetic chemistry in the pharmaceutical industry

P. Coleman, J. Alvarez, M. Truppo, 2019, Science.

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.

R. Miller, C. Strader, J. Metzger, 1998, The Journal of clinical investigation.

Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.

M. Struthers, R. Berger, S. Feighner, 2010, Bioorganic & medicinal chemistry letters.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2008, Bioorganic & medicinal chemistry letters.

Discovery of L-755,507: A subnanomolar human β3 adrenergic receptor agonist

C. Strader, M. Fisher, M. Wyvratt, 1998 .

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.

R. Miller, C. Strader, D. Macintyre, 1999, Bioorganic & medicinal chemistry letters.

Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.

M. Fisher, M. Wyvratt, A. Weber, 2001, Bioorganic & medicinal chemistry letters.

Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.

M. Fisher, M. Wyvratt, A. Weber, 2000, Bioorganic & medicinal chemistry letters.

Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.

J. Berger, S. Qureshi, Bei B. Zhang, 2007, European journal of pharmacology.

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

Margaret S. Wu, S. Qureshi, J. Mu, 2012, PloS one.

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.

J. Fenyk-Melody, S. Qureshi, D. Szalkowski, 2004, European journal of pharmacology.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.

D. Macintyre, M. Forrest, M. Fisher, 2000, Bioorganic & medicinal chemistry letters.

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

S. Qureshi, G. Jiang, J. Mu, 2011, Diabetologia.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

V. Ding, S. Qureshi, K. Chapman, 2011, Bioorganic & medicinal chemistry letters.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.

R. Miller, C. Strader, D. Macintyre, 1998, Bioorganic & medicinal chemistry letters.

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.

Ping Chen, N. Thornberry, B. Leiting, 2004, Bioorganic & medicinal chemistry letters.

Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.

A. Swensen, G. Kaczorowski, B. Priest, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.

K. Samuel, Haifeng Tang, B. Pio, 2021, Journal of medicinal chemistry.

Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.

J. Metzger, A. Swensen, M. Forrest, 2016, ACS medicinal chemistry letters.

Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.

J. Chen, R. Bentley, J. Metzger, 2015, ACS medicinal chemistry letters.

A survey of small molecule glucagon receptor antagonists from recent patents (2006 – 2010)

D. Shen, E. Parmee, Songnian Lin, 2011, Expert opinion on therapeutic patents.

Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.

M. Tota, J. Metzger, M. Forrest, 2003, Bioorganic & medicinal chemistry letters.

Crystallization and preliminary X-ray diffraction analysis of the catalytic domain of recombinant human phosphodiesterase 3B.

M. Tota, G. Scapin, J. W. Becker, 2004, Acta crystallographica. Section D, Biological crystallography.

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

Expression, refolding, and purification of recombinant human phosphodiesterase 3B: definition of the N-terminus of the catalytic core.

M. Tota, N. Morin, D. Macneil, 2004, Protein expression and purification.

Milbemycin synthesis : synthesis of 6β-hydroxy-3,4-dihydromilbemycin E

E. J. Thomas, E. Parmee, S. Karim, 1991 .

Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.

V. Ding, Bei B. Zhang, G. Kaczorowski, 2006, Bioorganic & Medicinal Chemistry.

New catalysts for the asymmetric aldol reaction: chiral boranes prepared from .alpha.,.alpha.-disubstituted glycine arenesulfonamides

Emma R. Parmee, Orin Tempkin, Satoru Masamune, 1991 .

The catalytic asymmetric aldol reaction of aldehydes with unsubstituted and monosubstituted silyl ketene acetals: formation of anti-β-hydroxy-α-methyl esters

E. Parmee, S. Masamune, Yaping Hong, 1992 .

Total synthesis of milbemycins: a synthesis of (6R)-6-hydroxy-3,4-dihydromilbemycin E.

E. J. Thomas, M. Helliwell, E. Parmee, 2005, Organic & biomolecular chemistry.

A total synthesis of milbemycin E

E. J. Thomas, P. Steel, E. Parmee, 1989 .

Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates

D. Wyss, A. Therien, T. Fischmann, 2022, Journal of Medicinal Chemistry.

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.

Andrew M Haidle, Matthew L. Maddess, J. Cumming, 2022, Journal of medicinal chemistry.

Total synthesis of milbemycin E: resolution of the C(1)–C(10)fragment and final assembly

E. J. Thomas, P. Steel, E. Parmee, 1997 .

The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective.

E. Parmee, Robert M Garbaccio, Emma R Parmee, 2016, Cell chemical biology.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.

Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.

M. Tota, G. Scapin, Suresh B. Singh, 2004, Biochemistry.

Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.

T. Roemer, S. Koseoglu, P. Tawa, 2017, Journal of medicinal chemistry.

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.

C. Strader, D. Macintyre, M. Forrest, 1999, Bioorganic & medicinal chemistry letters.

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.

J. Metzger, K. Maloney, K. Rosauer, 2020, Bioorganic & medicinal chemistry letters.

Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.

N. Thornberry, B. Leiting, Huaibing He, 2004, Bioorganic & medicinal chemistry letters.

Total synthesis of milbemycin E: development of a procedure for the introduction of the 3,4-double bond and synthesis of the C(1)–C(10) fragment

Nicholas A. Stacey, E. J. Thomas, S. Mortlock, 1997 .

Total Synthesis of Milbemycin E: Development of a Procedure for the Introduction of the 3,4‐Double Bond and Synthesis of the C(1)‐C(10) Fragment.

Nicholas A. Stacey, E. J. Thomas, O. S. Mills, 1997 .

Potent and selective proline derived dipeptidyl peptidase IV inhibitors.

N. Thornberry, B. Leiting, Sanjeev Kumar, 2004, Bioorganic & Medicinal Chemistry Letters.

Discovery of L-755,507: A Subnanomolar Human β3 Adrenergic Receptor Agonist.

C. Strader, M. Wyvratt, A. Weber, 1998 .

New Catalysts for the Asymmetric Aldol Reaction: Chiral Boranes Prepared from α,α-Disubstituted Glycine Arenesulfonamides.

E. Parmee, S. Masamune, A. Abiko, 1992 .

Facile Synthesis of Trisubstituted Thioindoles via a Novel Tricyclic Thiolactone Intermediate

Cangming Yang, E. Parmee, Q. Tan, 2009 .

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.